Pharmacogenetics: Therx perspective

Expert Review of Molecular Diagnostics

Volumn 1, Issue 3, 2001, Pages 255-263

  Renegar, Gaile ^a   Rieser, Patricia ^a   Manasco, Penelope ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

pharmacogenetics; SNP; SNP PRINT

Indexed keywords

ARTICLE; DIAGNOSTIC PROCEDURE; GENETIC POLYMORPHISM; HUMAN; MEDICAL ETHICS; PHARMACOGENETICS; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENETIC PROCEDURES; HEALTH CARE PERSONNEL; INFORMED CONSENT; LEGAL ASPECT; PRESCRIPTION; REVIEW; SIDE EFFECT; TREATMENT FAILURE;

ETHICS, MEDICAL; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

AMONAFIDE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DAPSONE; DEBRISOQUINE; DEXTROMETHORPHAN; DIAZEPAM; GLIPIZIDE; HEXOBARBITAL; IMIPRAMINE; ISONIAZID; LOSARTAN; MEPHENYTOIN; MERCAPTOPURINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OPIATE AGONIST; PHENACETIN; PHENFORMIN; PHENYTOIN; PROCAINAMIDE; PROGUANIL; SALAZOSULFAPYRIDINE; SULFADIMIDINE; TIOGUANINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

EID: 0035527708     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.1.3.255     Document Type: Article

References (22)

1. Stipp D. A DNA tragedy. Fortune 142, 170–175 (2000).
2. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 356, 1667–1671 (2000).
3. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci. 20, 342–349 (1999).
4. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet 356, 1255–1259 (2000).
5. To err is human: building a safer health system. Kohn LT, Corrigan JM, Donaldson M (Eds.), Institute of Medicine, Washington, DC, USA, (1999).
6. McDonald CJ, Weiner M, Hui SI. Deaths due to medical errors are exaggerated in Institute of Medicine Report. JAIVIA 284, 93–97 (2000).
7. Evans WE, Relling MV Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491 (1999).
8. Mancinelli L, Cronin M, Sadee W Pharmacogenomics: the promise of personalized medicine. Am. Acad. Pharmaceut. Li. Phatmsci. 2(1), article 4 (2000).
9. Manasco P, Rieser PA, Pericak-Vance M. Genes — here today, gone tomorrow: A clinician's guide to genetic linkage and association studies. Endocrinologist 10, 328–334 (2000).
10. Kuivenhoven JA, Jukema JW Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary athersclerosis. N. Engl. J. Med. 338, 86–93 (1998).
11. Arranz MJ, Munro J, Birkett J eta]. Pharmacogenetic prediction of clozapineresponse. Lancet 355, 615–1616 (2000).
12. Farlow MR, Lahiri DK, Poirier J, Davignon J Hui S. Apoplipoprotein E genotype and gender influence response to tacrine therapy. Ann. NT Acad. Li. 802, 101–110 (1996).
13. Drysdale CM, McGraw DVV, Stack CB, et al. Complex promoter and coding region 132-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci. USA 97, 10483–10488 (2000).
14. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001).
15. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 355, 1358–1361 (2000).
16. Stephens JC, Schneider JA, Tanguay DA et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 293, 489–493 (2001).
17. Kleyn PVV, Vesell ES. Genetic variation as a guide to drug development. Science 281, 1820–1821 (1998).
18. Lichter J, McNamara D. What's in a gene: using genetic information for the design of clinical trials. Gum Opin. Biotechnol 6, 715–717 (1995).
19. Roses AD. Pharmacogenetics and the practice of medicine. Nature 405, 857–865 (2000).
20. Nelson R. We need a postmarketing drug development process Phatmacoepidemiol Drug- Safety 9, 253–355 (2000).
21. Hodgson J. First Genetic Trust banks on genes. Business Reg: News 18 (12), 1236 (2000).
22. Knoppers BM, Hirtle M, Lormeau S, Laberge CM, Laflamme M. Control of DNA samples and information. Genomics. 50, 385–401 (1998).